KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Interest & Investment Income (2017 - 2024)

Palvella Therapeutics has reported Interest & Investment Income over the past 7 years, most recently at $241000.0 for Q3 2022.

  • Quarterly Interest & Investment Income rose 5925.0% to $241000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $364000.0 through Sep 2022, up 1922.22% year-over-year, with the annual reading at $4000.0 for FY2021, 99.22% down from the prior year.
  • Interest & Investment Income was $241000.0 for Q3 2022 at Palvella Therapeutics, up from $132000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $662000.0 in Q2 2018 and troughed at -$6000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $241000.0 (2022), against an average of $240052.6.
  • The largest YoY upside for Interest & Investment Income was 5925.0% in 2022 against a maximum downside of 200.0% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $471000.0 in 2018, then dropped by 18.9% to $382000.0 in 2019, then tumbled by 97.91% to $8000.0 in 2020, then plummeted by 175.0% to -$6000.0 in 2021, then soared by 4116.67% to $241000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Interest & Investment Income are $241000.0 (Q3 2022), $132000.0 (Q2 2022), and -$3000.0 (Q1 2022).